Background: Osteoporosis, a prevalent chronic metabolic bone disease, is mostly associated with variables such as menopause and age. It is characterized by a heightened susceptibility to bone fractures due to increased bone fragility. While it may affect individuals of all age groups, genders, and ethnicities, it is more prevalent among Caucasians (individuals of white race), elderly individuals, and women. Due to a growing elderly population and extended lifespan, osteoporosis is progressively emerging as a worldwide pandemic. Presently, the estimated number of individuals afflicted with osteoporosis exceeds 200 million. Managing osteoporosis requires a comprehensive strategy including lifestyle adjustments, pharmaceutical interventions, fall prevention methods, and frequent monitoring. Medical research and treatment advancements have greatly enhanced the capacity to prevent and control osteoporosis, hence decreasing the likelihood of fractures and improving the overall well-being of those afflicted. Aim: To evaluate the evidence for efficacy of treatment options to reduce osteoporotic fracture risk for men. Materials and method: A systematic research was carried during june 2021 to December 2022 using MeSH terms osteoporosis, bisphonates, bone resorption, bone remodelling in PubMed, Scopus, Embase, Cochrane databases. Conclusion:Bisphosphonates reduce vertebral and possibly nonvertebral fracture risk for men with osteoporosis. Further studies are needed to evaluate the efficacy of bisphosphonates for reducing nonvertebral fracture risk for men, and to evaluate the efficacy of non-bisphosphonate treatment options such as denosumab or teriparatide to reduce vertebral and nonvertebral fracture risk for men.